Phenotypic predictors of response to Simvastatin therapy among African-Americans and Caucasians: The cholesterol and pharmacogenetics (CAP) study

American Journal of Cardiology

Volumn 97, Issue 6, 2006, Pages 843-850

  Simon, Joel A ^a,b   Lin, Feng ^b   Hulley, Stephen B ^b   Blanche, Patricia J ^c   Waters, David ^b   Shiboski, Stephen ^b   Rotter, Jerome I ^d,e   Nickerson, Deborah A ^f   Yang, Huiying ^d,e   Saad, Mohammed ^g   Krauss, Ronald M ^c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG RESPONSE; ETHNOLOGY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SMOKING; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AFRICAN AMERICANS; AGE FACTORS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DEMOGRAPHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHENOTYPE; SEX FACTORS; SIMVASTATIN; SMOKING; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33644609683     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.09.134     Document Type: Article

References (11)

1. W.T. Friedewald, R.I. Levy, D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
2. SAS Institute Statistical analysis system, version 8.02 2001 SAS Institute Cary, North Carolina
3. C.L. Shear, F.A. Franklin, S. Stinnett, D.P. Hurley, R.H. Bradford, A.N. Chremos, D.T. Nash, A. Langendorfer Expanded Clinical Evaluation of Lovastatin (EXCEL) study results effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins Circulation 85 1992 1293 1303
4. D. Hunt, P. Young, J. Simes, W. Hague, S. Mann, D. Owensby, G. Lane, A. Tonkin Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary disease are equal to or exceed those seen in younger patients results from the LIPID trial Ann Intern Med 134 2001 931 940
5. W.B. Kannel, R.B. D'Agostino, M. Stepanians, L.C. D'Agostino Efficacy and tolerability of lovastatin in a six-month study analysis by gender, age and hypertensive status Am J Cardiol 66 suppl 1990 1B 10B
6. S.J. Lewis, L.A. Moye, F.M. Sacks, D.E. Johnstone, G. Timmis, J. Mitchell, M. Limacher, S. Kell, S.P. Glasser, J. Grant Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range results of the Cholesterol and Recurrent Events (CARE) trial Ann Intern Med 129 1998 681 689
7. L. Ose, O. Luurila, J. Eriksson, A. Olsson, H. Lithell, B. Widgren Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia a multinational, randomised, double-blind study Curr Med Res Opin 15 1999 228 240
8. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, A.M. Gotto Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
9. J.A. Simon, J. Fong, J.T.J. Bernert, W.S. Browner Relation of smoking and alcohol consumption to serum fatty acids Am J Epidemiol 144 1996 325 334
10. H.J. Milionis, E. Rizos, D.P. Mikhailidis Smoking diminishes the beneficial effect of statins observations from the landmark trials Angiology 52 2001 575 587
11. K.J. Rothman No adjustments are needed for multiple comparisons Epidemiology 1 1990 43 46